Showing 1781-1790 of 2105 results for "".
- FDA Provides Expanded Clearance for Device to Treat Migraine in Childrenhttps://practicalneurology.com/news/fda-provides-expanded-clearance-for-device-to-treat-migraine-in-children/2468822/The Food and Drug Administration (FDA) has granted new marketing clearance for a device that provides acute and preventive treatment of migraine to include children 12 years of age and older. The technology (sTMS; eNeura, Inc., Baltimore, MD) is a non-invasive device that uses single-puls
- Plasma p-tau217 Clock Models Estimate Time to Symptomatic Alzheimer Diseasehttps://practicalneurology.com/news/plasma-p-tau217-clock-models-estimate-time-to-symptomatic-alzheimer-disease/2485769/A single plasma % phosphorylated tau217 (%p-tau217) measurement may estimate not only risk but also timing of symptomatic Alzheimer disease (AD) onset, according to a longitudinal cohort study published in Nature Medicine. In 2 independent cohorts, clock models based on plasma %p-tau217
- Maternal COVID-19 Exposure Linked to Neurodevelopmental Risk in Childrenhttps://practicalneurology.com/news/maternal-covid-19-exposure-linked-to-neurodevelopmental-risk-in-children/2485480/Children exposed to maternal COVID-19 (SARS-CoV-2 infection) in utero had a higher likelihood of receiving a neurodevelopmental diagnosis by age 3 years, with the strongest associations observed following third-trimester exposure and among male offspring, according to a large retrospective cohort
- Director of the National Institute of Neurological Disorders and Stroke Oustedhttps://practicalneurology.com/news/director-of-the-national-institute-of-neurological-disorders-and-stroke-ousted/2485145/The contract for Walter Koroshetz, MD, as Director of the National Institute of Neurological Disorders and Stroke (NINDS) has not been renewed, ending his leadership of the institute after 10 years. Dr. Koroshetz’s departure comes despite a positive internal review and a recommendation for reappo
- CTAD 2025 Honors Takeshi Iwatsubo, MD, PhD with Lifetime Achievement Awardhttps://practicalneurology.com/news/ctad-2025-honors-takeshi-iwatsubo-md-phd-with-lifetime-achievement-award/2484692/Takeshi Iwatsubo, MD, PhD was recognized at the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference as the recipient of this year’s Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. The award celebrates Dr. Iwatsubo’s decades of foundational work in Alzheime
- Intrathecal Gene Therapy Approved for Adults, Older Children with Spinal Muscular Atrophyhttps://practicalneurology.com/news/intrathecal-gene-therapy-approved-for-adults-older-children-with-spinal-muscular-atrophy/2484610/The Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve; Novartis, Basel, Switzerland) for the treatment of people aged 2 years and older with spinal muscular atrophy (SMA) and a confirmed survival motor neuron 1 (SMN1) gene mutation. The adeno-associated vir
- First Thymidine Kinase 2 Deficiency Treatment Receives FDA Nodhttps://practicalneurology.com/news/first-thymidine-kinase-2-deficiency-treatment-receives-fda-nod/2484324/The Food and Drug Administration (FDA) has approved Kygevvi (doxecitine and doxribtimine; UCB, Brussels, Belgium) for the treatment of adult and pediatric patients with thymidine kinase 2 deficiency (TK2d) with an age of symptom onset at or before 12 years. Kygevvi is the first and only therapy a
- Blood-Based P-Tau181 Testing for Alzheimer’s Pathology Now Cleared by the FDA for the Primary Care Settinghttps://practicalneurology.com/news/blood-based-p-tau181-testing-for-alzheimers-pathology-now-cleared-by-the-fda-for-the-primary-care-setting/2484309/The Food and Drug Administration (FDA) has granted 510(k) clearance to Elecsys pTau181 (Roche, Basel, Switzerland), the first blood-based biomarker assay authorized to aid in the initial assessment of Alzheimer disease (AD) and other causes of cognitive decline for people aged ≥55 years in the pr
- Artificial Sweeteners Linked to Faster Cognitive Decline in Midlife Adultshttps://practicalneurology.com/news/artificial-sweeteners-linked-to-faster-cognitive-decline-in-midlife-adults/2484026/Higher consumption of low- and no-calorie sweeteners (LNCSs) was associated with accelerated cognitive decline, particularly in verbal fluency and global cognition, among adults aged <60 years. This finding from a longitudinal study published in Neurology contributes to a growing body
- 2024 McDonald Criteria Revisions Published in The Lancet Neurologyhttps://practicalneurology.com/news/2024-mcdonald-criteria-revisions-published-in-the-lancet-neurology/2483516/The 2024 revisions to the McDonald criteria for the diagnosis of multiple sclerosis (MS) have been published in The Lancet Neurology in September 2025, marking the first major update since 2017. The criteria were updated to reflect significant changes in the field, including an evolving